eMeasure Title

Pregnant women that had HBsAg testing
eMeasure Identifier (Measure Authoring Tool) 158 eMeasure Version number 4.0.000
NQF Number Not Applicable GUID 3bbfc929-50c8-44b8-8d34-82be75c08a70
Measurement Period January 1, 20XX through December 31, 20XX
Measure Steward Optum
Measure Developer Optum
Endorsed By None
Description 
This measure identifies pregnant women who had a HBsAg (hepatitis B) test during their pregnancy.
Copyright 
(C) 2015 Optum, Inc.  All rights reserved.
Disclaimer 
The information in this document is subject to change without notice. This documentation contains proprietary information, and is protected by U.S. and international copyright. All rights reserved. No part of this documentation may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, modifying, or recording, without the prior written permission of Optum, Inc. No part of this documentation may be translated to another program language without the prior written consent of Optum, Inc.

Optum(R), Symmetry(R), EBM Connect(R), service marks and logos are registered and unregistered trademarks of Optum and its affiliates in the United States and other countries. 

EBM Connect(R), Release 9.0, 2015
Measure Scoring Proportion
Measure Type Process
Stratification 
None
Risk Adjustment 
None
Rate Aggregation 
None
Rationale 
The USPSTF found good evidence that universal prenatal screening for HBV infection using HBsAg substantially reduces prenatal transmission of HBV and the subsequent development of chronic HBV infection (USPSTF 2004). The current practice of vaccinating all infants against HBV infection and post-exposure prophylaxis with hepatitis B immune globulin administered at birth to infants of HBV-infected mothers substantially reduces the risk for acquiring HBV infection.
Clinical Recommendation Statement 
The U.S. Preventive Services Task Force (USPSTF) strongly recommends screening for hepatitis B virus (HBV) infection in pregnant women at their first prenatal visit (USPSTF 2004). This is a grade A* recommendation from the USPSTF. In addition, the American College of Obstetricians and Gynecologists (ACOG) recommend screening all pregnant women for HBV infection (ACOG 2002).
Improvement Notation 
Higher score indicates better quality
Reference 
U.S. Preventive Services Task Force. Screening for Hepatitis B Virus Infection in Pregnancy: U.S.Preventive Services Task Force Reaffirmation Recommendation Statement. Ann Int Med 2009;150:869-73.
Reference 
American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 86: Viral hepatitis in pregnancy. Obstet Gynecol 2007;110:941-56.[PMID: 17906043]
Definition 
None
Guidance 
None
Transmission Format 
TBD
Initial Population 
All female patients aged 12 and older who had a live birth or delivery during the measurement period.
Denominator 
Equals Initial Population.
Denominator Exclusions 
None
Numerator 
Patients who were tested for Hepatitis B surface antigen (HBsAg) during pregnancy within 280 days prior to delivery.
Numerator Exclusions 
Not Applicable
Denominator Exceptions 
Patients with current or past Hepatitis B infection.
Measure Population 
Not Applicable
Measure Population Exclusions 
Not Applicable
Measure Observations 
Not Applicable
Supplemental Data Elements 
For every patient evaluated by this measure also identify payer, race, ethnicity and sex.

Table of Contents


Population Criteria

Data Criteria (QDM Variables)

Data Criteria (QDM Data Elements)

Supplemental Data Elements

Risk Adjustment Variables


Measure Set 
None